Andra AP fonden Has $15.50 Million Stock Holdings in United Therapeutics Corporation $UTHR

Andra AP fonden trimmed its stake in United Therapeutics Corporation (NASDAQ:UTHR) by 11.7% in the first quarter, Holdings Channel reports. The firm owned 26,144 shares of the biotechnology company’s stock after selling 3,456 shares during the quarter. Andra AP fonden’s holdings in United Therapeutics were worth $15,503,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Leuthold Group LLC increased its stake in shares of United Therapeutics by 41.4% during the 4th quarter. Leuthold Group LLC now owns 10,672 shares of the biotechnology company’s stock worth $5,200,000 after purchasing an additional 3,126 shares during the last quarter. UBS Group AG grew its holdings in United Therapeutics by 45.3% during the fourth quarter. UBS Group AG now owns 225,849 shares of the biotechnology company’s stock worth $110,045,000 after purchasing an additional 70,445 shares during the period. Perpetual Ltd acquired a new position in United Therapeutics during the fourth quarter worth approximately $1,059,000. SG Americas Securities LLC increased its position in United Therapeutics by 88.6% during the fourth quarter. SG Americas Securities LLC now owns 26,960 shares of the biotechnology company’s stock worth $13,136,000 after buying an additional 12,663 shares during the last quarter. Finally, Brookstone Capital Management raised its stake in United Therapeutics by 25.4% in the fourth quarter. Brookstone Capital Management now owns 6,622 shares of the biotechnology company’s stock valued at $3,227,000 after buying an additional 1,342 shares during the period. Institutional investors and hedge funds own 94.08% of the company’s stock.

United Therapeutics Price Performance

United Therapeutics stock opened at $535.83 on Wednesday. The stock’s fifty day moving average price is $550.65 and its two-hundred day moving average price is $530.90. United Therapeutics Corporation has a one year low of $272.12 and a one year high of $609.35. The firm has a market cap of $22.75 billion, a PE ratio of 19.78, a price-to-earnings-growth ratio of 1.77 and a beta of 0.58.

United Therapeutics (NASDAQ:UTHR) last released its earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share for the quarter, missing analysts’ consensus estimates of $7.00 by ($1.18). United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. The company had revenue of $781.50 million for the quarter, compared to the consensus estimate of $797.40 million. During the same quarter in the previous year, the company posted $6.63 earnings per share. The business’s revenue was down 1.6% compared to the same quarter last year. Sell-side analysts expect that United Therapeutics Corporation will post 26.63 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, EVP Paul A. Mahon sold 8,300 shares of the business’s stock in a transaction that occurred on Thursday, July 2nd. The shares were sold at an average price of $552.56, for a total value of $4,586,248.00. Following the completion of the transaction, the executive vice president directly owned 45,172 shares in the company, valued at approximately $24,960,240.32. The trade was a 15.52% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Martine A. Rothblatt sold 9,500 shares of the company’s stock in a transaction that occurred on Monday, July 13th. The stock was sold at an average price of $535.99, for a total transaction of $5,091,905.00. Following the sale, the chief executive officer directly owned 40,513 shares of the company’s stock, valued at approximately $21,714,562.87. This trade represents a 19.00% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 535,379 shares of company stock valued at $299,468,343 over the last quarter. 8.60% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

UTHR has been the subject of a number of recent analyst reports. Wells Fargo & Company raised United Therapeutics from an “equal weight” rating to an “overweight” rating and raised their price objective for the company from $575.00 to $735.00 in a research report on Thursday, May 7th. Royal Bank Of Canada increased their price target on United Therapeutics from $701.00 to $704.00 and gave the company an “outperform” rating in a research note on Tuesday, July 7th. Raymond James Financial initiated coverage on United Therapeutics in a report on Friday, April 10th. They set an “outperform” rating and a $700.00 price target for the company. Morgan Stanley set a $516.00 price objective on shares of United Therapeutics in a research report on Thursday, May 7th. Finally, Weiss Ratings restated a “buy (b)” rating on shares of United Therapeutics in a research note on Thursday, June 11th. Ten research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $644.82.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.